Anti-HIV and anti-inflammatory action of iodine-lithium-α-dextrin is accompanied by the improved quality of life in AIDS patients Online publication date: Wed, 27-Jun-2007
by Levon M. Mkhitaryan, Tigran K. Davtyan, Emil S. Gabrielyan, Levon A. Gevorkyan
International Journal of Biotechnology (IJBT), Vol. 9, No. 3/4, 2007
Abstract: Clinical efficacy, tolerability and safety of various doses of Iodine-Lithium-α-Dextrin (ILαD) monotherapy have been evaluated in 56 HIV-infected patients enrolled in double blind uncontrolled randomised study during 48 weeks follow-up period. ILαD was administered intravenously three times over five days with intervals of 2–3 weeks between treatments for a total of 12 infusions in 4 cycles. HIV-1 RNA reduction and increase of CD4+ T-cell counts as well as decrease of serum levels of IgG, IgA, β2 microglobulin, tumour necrosis factor-α and soluble interleukin-2 receptor were observed on 4–24th weeks. Quality of life was dramatically improved on 4–48th weeks and more. The side-effects were phlebitis of punctured small veins and subfebrile fever, that did not lead to discontinuation of the treatment and did not require special treatment. ILαD appears to be safe and can be used as an adjuvant therapy for long term improvement of quality of life in AIDS patients.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook